Recent Updates
Recently added Catalysts
VTGN Positive Sentiment

VistaGen Therapeutics to Participate in Baird’s 2021 Global Healthcare Conference

Key Takeaway: VistaGen Therapeutics will participate in Baird's 2021 Global Healthcare Conference on September 14. CEO Shawn Singh will lead a fireside chat, and the company will hold one-on-one meetings during the event. A live webcast of the presentation will be available on their website.
Price reaction · baseline $94.2 (2021-09-07 close) · hit pre-market · 1 other VTGN headline(s) in the window, move may be shared
day 0 close · peak
-0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • VistaGen is participating in a prominent healthcare conference.
  • The company is focused on innovative treatments for CNS disorders.
  • Management will engage in direct discussions with investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~6 mo
Medium dilution risk
Lead asset
AV-101
Phase 1 · Healthy

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) --VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that management will participate in Baird’s 2021 Global Healthcare Conference, including a fireside chat with Shawn Singh, Chief Executive Officer, on Tuesday, September 14 at 12:10 p.m. Pacific Time and one-on-one meetings throughout the two-day conference.
A live webcast of VistaGen’s presentation will be accessible through theNews/Eventspage of the Investors section of the Company’s website atwww.VistaGen.com.
About VistaGenVistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date, and has therapeutic potential in multiple CNS markets. For more information, please visitwww.VistaGen.comand connect with VistaGen onTwitter,LinkedIn, and Facebook.

VistaGen Company Contacts

Frequently Asked Questions

When is VistaGen participating in the conference?

VistaGen will participate in the conference on September 14, 2021.

Who will represent VistaGen at the conference?

CEO Shawn Singh will lead a fireside chat at the conference.

Where can I watch VistaGen's presentation?

A live webcast of VistaGen's presentation will be available on their website.

What is the focus of VistaGen's drug candidates?

VistaGen's drug candidates target anxiety, depression, and CNS disorders.

Last updated: Sep 8, 2021